Property & Building buys Fla. project

SSCC will provide 15% of the cost itself (of which PBC will provide 75%). The remaining 85% will come in the form of a non-recourse bank loan to SSCC.

By DANIEL KENNEMER
October 17, 2005 06:52
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Property and Building Corporation Ltd. (known in Hebrew as Nekhasim u-Binyan) said Sunday its Delaware-based subsidy PBC USA Investments Inc. would acquire 75 percent of the rights in Station Square Clearwater Condo, LLC (SSCC). SSCC is set to complete the purchase of construction rights for a site in Tampa, Florida, on which it plans to build a mixed-use project, including 126 residential units and 10,000 square feet of retail at a total cost of roughly $57 million. SSCC will provide 15% of the cost itself (of which PBC will provide 75%). The remaining 85% will come in the form of a non-recourse bank loan to SSCC.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS